The novel drug category of sodium-glucose cotransporter 2 (SGLT2) inhibitors has cardioprotective effects in patients with HF through various mechanisms, including improvement of endothelial function, aside from their established effectiveness in the treatment of diabetes mellitus [234]. This evidence concerns the gene SLC5A2 and diabetes mellitus.